ISSN 2619-9734
Most Accessed Articles - UPDATES IN CARDIOLOGY OF THE TURKISH SOCIETY OF CARDIOLOGY

Most Accessed Articles

1.Pharmacological properties of nebivolol
Ipek Komşuoğlu Çelikyurt
doi: 10.5543/ucard.2019.21931   2019; 2 - 1 | Pages 7 - 14

REVIEW
2.2017 ESC/EACTS Guidelines for the management of valvular heart disease
Helmut Baumgartner, Volkmar Falk, Jeroen J. Bax, Michele De Bonis, Christian Hamm, Per Johan Holm, Bernard Iung, Patrizio Lancellotti, Emmanuel Lansac, Daniel Rodriguez Munoz, Raphael Rosenhek, Johan Sjögren, Pilar Tornos Mas, Alec Vahanian, Thomas Walther, Olaf Wendler, Stephan Windecker, Jose Luis Zamorano
doi: 10.1093/eurheartj/ehx391   2018; 1 - 2 | Pages 1 - 53
Abstract |Full Text PDF

INVITED REVIEW
3.Beta-blockers in cardiovascular prevention
Barış Ilerigelen
doi: 10.5543/ucard.2019.00719   2019; 2 - 1 | Pages 1 - 6

4.Nebivolol in the treatment of systemic hypertension
Fatih Sinan Ertaş
doi: 10.5543/ucard.2019.76486   2019; 2 - 1 | Pages 15 - 19

5.Approach to secondary prevention patient in the 2019 European Society of Cardiology Dyslipidemia Guide
Meral Kayıkçıoğlu
doi: 10.5543/ucard.2019.98608   2020; 3 - 1 | Pages 7 - 9

REVIEW
6.Sakubitril/valsartan’ın kalp yetersizliğinde yarar sağlayan etki mekanizmaları nelerdir?
Lütfü Bekar
doi: 10.5543/ucard.2020.92485   2020; 3 - 2 | Pages 1 - 3
Abstract |Full Text PDF

7.Guide on advanced heart failure
Sanem Nalbantgil, Yüksel Çavuşoğlu, Bahri Akdeniz, Hakan Altay, Ahmet Çelik, Çağatay Engin, Tolga Sinan Güvenç, Bülent Mutlu, Gökçen Orhan, Bülent Özin, Ahmet Temizhan, Dilek Ural, Nesligül Yıldırım, Mehmet Birhan Yılmaz
doi: 10.5543/ucard.2018.43153   2018; 1 - 1 | Pages 1 - 79

8.Böbrek fonksiyonlarına göre sakubitril/valsartan yönetimi nasıl yapılmalıdır?
Ahmet Temizhan, Mustafa Arıcı
doi: 10.5543/ucard.2020.77486   2020; 3 - 2 | Pages 72 - 77
Abstract |Full Text PDF

9.Statin intolerance
Özcan Başaran
doi: 10.5543/ucard.2019.09719   2020; 3 - 1 | Pages 20 - 24

10.Risk scoring and primary prevention
Öner Özdoğan
doi: 10.5543/ucard.2019.69188   2020; 3 - 1 | Pages 3 - 6

11.Diet and lifestyle modifications
Ümit Yaşar Sinan
doi: 10.5543/ucard.2019.02996   2020; 3 - 1 | Pages 25 - 29

12.Introduction to 2019 ESC/EAS Guidelines for the Management of Dyslipidema
Lale Tokgözoğlu
doi: 10.5543/ucard.2019.25744   2020; 3 - 1 | Pages 1 - 2
Abstract |Full Text PDF

13.What is the NTproBNP response to sacubitril / Valsartan treatment and how does the NTproBNP response correlate with clinical benefit?
Ilke Sipahi
doi: 10.5543/ucard.2020.83997   2020; 3 - 2 | Pages 86 - 87
Abstract |Full Text PDF

INVITED REVIEW
14.Clinical trials with nebivolol in Turkey
Mustafa Kılıçkap
doi: 10.5543/ucard.2019.66375   2019; 2 - 1 | Pages 25 - 30

REVIEW
15.Türkiye’de ki sakubitril/valsartan deneyimi (ARNi-TR) klinik çalışmalardaki verilerle ne kadar örtüşüyor?
Berkay Ekici, Mehdi Zoghi
doi: 10.5543/ucard.2020.02486   2020; 3 - 2 | Pages 123 - 125
Abstract |Full Text PDF

INVITED REVIEW
16.Nebivolol in heart failure teatment
Ahmet Temizhan
doi: 10.5543/ucard.2019.33042   2019; 2 - 1 | Pages 20 - 24

17.Lipid therapy in young and elderly
Ceyhun Ceyhan, Fatih Sivri
doi: 10.5543/ucard.2019.65375   2020; 3 - 1 | Pages 16 - 19

REVIEW
18.Sakubitril/valsartan’ın doz titrasyonu hangi hastada nasıl yapılmalı?
Zeki Öngen, Eser Durmaz
doi: 10.5543/ucard.2020.58077   2020; 3 - 2 | Pages 53 - 55
Abstract |Full Text PDF

19.Lipid lowering therapy in particular patient populations
Barış Güngör
doi: 10.5543/ucard.2019.09797   2020; 3 - 1 | Pages 10 - 15

20.Sakubitril/valsartan tedavisi sırasında diüretik tedavi yönetimi nasıl olmalı?
Zerrin Yigit
doi: 10.5543/ucard.2020.07279   2020; 3 - 2 | Pages 67 - 69
Abstract |Full Text PDF

Quick Search



Copyright © 2024 Update in Cardiology



Kare Publishing is a subsidiary of Kare Media.